Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06607692 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Study acronym: LUPARPED
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv4
  2. Phase: Phase 2 to Phase 1/2v3 Show 5 more changesShow less
    • Primary endpoints: 1 to 2
    • Start date changed from estimate of Oct 2024 to Sep 20, 2024
    • Eligibility criteria shortened, about 21 words
    • Secondary endpoints expanded, about 33 words
    • Study description expanded, about 56 words
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
Trial Details
NCT Number NCT06607692
Lead Sponsor Fundación de investigación HM
Conditions
(from sponsor)		 Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumours (NET) +14 more
Related terms Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Esthesioneuroblastoma, Olfactory, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors, Osteosarcoma, Paraganglioma, Pheochromocytoma, Recurrence, Sarcoma, Synovial
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov